Last updated
Boehringer Ingelheim: Product Launch
Boehringer Ingelheim reported first-half 2026 sales growth of 16.2% (EUR 15.8 billion), driven by strong U.S. performance including increased demand for JARDIANCE® and successful new product launches.
Source: GNW — Germany
The leadership read
Product momentum tends to widen biotech & pharma product and commercial leadership bench strength.
Market context: The wider read — a Talent Market Index of 107.9 (Hot), up 2.4 month-on-month — shows Americas signal flow rising (+15.4pts).
Boehringer Ingelheim: 4 signals in the last 90 days — above the Biotech & Pharma median of 1 across 25 tracked companies; 0.2% of MitchelLake's Americas signal flow; 4 tracked across 41 days.
MitchelLake in this thematic
Also at Boehringer Ingelheim →
More signals across Biotech & Pharma
Product Launch · Americas
Bristol Myers Squibb →Bristol Myers Squibb announced FDA acceptance of its New Drug Application for mezigdomide, an oral CELMoD candidate for relapsed or refractory multiple myeloma combination therapy.
Product Launch · Americas
Bota Biosciences →Bota Biosciences released Biology Protocol Language (BPL) and BPL-COGEN, a compiler-verified protocol language and generation pipeline for AI-driven biomanufacturing, announced on bioRxiv.
Product Launch · Americas
Neurocrine Biosciences →Neurocrine presented CRENESSITY clinical data at ENDO 2026 demonstrating hormone normalization in classic CAH and two-year cardiometabolic and bone health outcomes in adults.
Product Launch · Americas
Merck & Co., Inc. →Merck presenting oncology strategy with focus on clinical progress and pipeline diversification, indicating new program developments and potential launches
Product Launch · Americas
Thermo Fisher Scientific →Thermo Fisher launched new AI-enabled Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at ASMS Conference, integrating with Olink proteomics and recent AI-focused software acquisitions to strengthen competitive positioning in life sciences tools.
Product Launch · Americas
BridgeBio →BridgeBio submitted NDA to FDA for BBP-418 for LGMD2I/R9 treatment, based on positive Phase 3 FORTIFY trial results showing statistically significant improvements
Intelligence powered by Autonodal ↗